Other equities analysts have also recently issued research reports about the company. HC Wainwright set a $28.00 price target on Urovant Sciences and gave the stock a buy rating in a report on Monday, June 24th. Zacks Investment Research cut Urovant Sciences from a hold rating to a sell rating in a report on Wednesday, May 22nd. Finally, JPMorgan Chase & Co. set a $24.00 price target on Urovant Sciences and gave the stock a buy rating in a report on Friday, June 14th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $21.63.
Shares of NASDAQ:UROV traded down $0.35 during trading on Thursday, reaching $7.85. 38,941 shares of the company traded hands, compared to its average volume of 18,504. The business’s 50 day moving average price is $8.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 8.34 and a current ratio of 8.34. Urovant Sciences has a 52 week low of $4.05 and a 52 week high of $14.49.
In other news, major shareholder Holdings Ltd. Dexxon bought 11,608 shares of the stock in a transaction on Friday, May 17th. The stock was acquired at an average price of $7.10 per share, with a total value of $82,416.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Andrew Lo bought 18,204 shares of the stock in a transaction on Wednesday, June 19th. The stock was purchased at an average cost of $8.32 per share, with a total value of $151,457.28. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 167,952 shares of company stock valued at $1,330,019.
A number of institutional investors and hedge funds have recently modified their holdings of UROV. FMR LLC increased its holdings in Urovant Sciences by 28.4% in the 1st quarter. FMR LLC now owns 1,710,836 shares of the company’s stock worth $17,194,000 after purchasing an additional 378,135 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Urovant Sciences in the first quarter valued at about $325,000. Two Sigma Investments LP acquired a new stake in shares of Urovant Sciences in the fourth quarter valued at about $72,000. Barclays PLC acquired a new stake in shares of Urovant Sciences in the fourth quarter valued at about $37,000. Finally, Marshall Wace North America L.P. acquired a new stake in shares of Urovant Sciences in the first quarter valued at about $49,000. 21.92% of the stock is owned by institutional investors and hedge funds.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Featured Story: How are the companies in the S&P 500 selected?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.